8-K: Vicarious Surgical Raises $5.9M in Direct Offering

Vicarious Surgical Inc. announced the pricing of a $5.9 million registered direct offering and concurrent private placement of common stock and warrants with an institutional investor.

Summary

• Vicarious Surgical Inc. entered into a securities purchase agreement with an institutional investor for a registered direct offering and concurrent private placement.
• The offering is expected to generate approximately $5.9 million in gross proceeds.
• The registered direct offering includes 588,300 shares of Class A common stock and pre-funded warrants to purchase up to 561,700 shares of Common Stock.
• The concurrent private placement includes Series A and Series B common warrants, each to purchase up to 1,150,000 shares of Class A common stock.
• The pre-funded warrants have an exercise price of $0.0001 and are immediately exercisable.
• The common warrants have an exercise price of $5.10 and will be exercisable upon stockholder approval, expiring five years from that date.
• The combined effective purchase price for one share of Class A common stock and accompanying warrants to purchase two shares of Class A common stock is $5.10.
• The combined purchase price for one pre-funded warrant and accompanying warrants to purchase two shares of Class A common stock is $5.0999.
• Lake Street Capital Markets, LLC is acting as the exclusive placement agent, receiving a 6.0% cash fee and up to $100,000 for expenses.
• Proceeds are intended for general corporate purposes, including working capital, capital expenditures, or research and development.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for operations and R&D, which is positive for a growth company. However, the significant potential dilution from warrants and the need for stockholder approval for common warrants introduce some uncertainty and downside risk for existing shareholders. The terms are generally in line with market expectations for this type of financing.

Positives

• Secured approximately $5.9 million in gross proceeds, strengthening the company's financial position for general corporate purposes, working capital, capital expenditures, and R&D.
• The offering includes pre-funded warrants with a nominal exercise price ($0.0001), providing immediate exercisability and potential for future capital infusion upon full exercise.
• The company has a clear plan to seek stockholder approval for the common warrants, demonstrating adherence to corporate governance.
• The inclusion of a call provision for Series B Common Warrants allows the company to repurchase them under favorable stock price and volume conditions, potentially reducing future dilution.

Negatives

• The issuance of a significant number of warrants (2.3 million common warrants plus pre-funded warrants for 561,700 shares) could lead to substantial future dilution for existing shareholders upon exercise.
• The common warrants require stockholder approval to become exercisable, introducing uncertainty and a potential delay in realizing the full capital benefit from their exercise.
• The company has agreed to restrictions on issuing additional common stock or equivalents for 60 days and variable rate transactions for 120 days, limiting immediate financing flexibility.
• Placement agent fees of 6.0% of gross proceeds and up to $100,000 in expenses will reduce the net proceeds received by the company.

Risks

• Future dilution from the exercise of pre-funded warrants and common warrants.
• Uncertainty and potential delays in obtaining stockholder approval for the exercise of common warrants.
• Market price volatility of the Common Stock could negatively impact the value of the warrants and the company's ability to execute the Series B warrant call provision.
• The company's ability to maintain its listing on the New York Stock Exchange.
• Risks related to the approval, commercialization, and adoption of the company's product candidates, including the Vicarious Surgical System.
• Changes in applicable laws or regulations affecting the company's business.
• The company's ability to raise future financing.
• The success, cost, and timing of product and service development activities.
• The company's ability to obtain and maintain regulatory approval for its products.
• Competition from other companies in the surgical robotics market.
• Economic downturns, political, and market conditions adversely affecting the company's business.
• Intellectual property rights and the ability to protect or enforce them.

Future Outlook

The company expects to use the proceeds from the offering for general corporate purposes, including working capital, capital expenditures, or research and development expenditures. It also plans to hold a stockholder meeting within 120 days to seek approval for the exercise of common warrants and will file a resale registration statement for the common warrant shares within 45 days, aiming for effectiveness within 90 days.

Management Comments

• We expect to use the proceeds from the proposed offering for general corporate purposes, which may include working capital, capital expenditures, or research and development expenditures.

Industry Context

Vicarious Surgical operates in the highly competitive and capital-intensive surgical robotics industry. This capital raise is a common strategy for growth-stage medical technology companies to fund ongoing research and development, clinical trials, and commercialization efforts for innovative surgical systems like the Vicarious Surgical System. The need for frequent capital raises highlights the significant investment required to bring advanced robotic surgical platforms to market and compete with established players.

Comparison to Industry Standards

• The capital raise structure, involving a combination of common stock and warrants, is a common financing mechanism for early to mid-stage medical technology companies, similar to those used by peers in the surgical robotics space such as Intuitive Surgical (ISRG) in its earlier stages or emerging competitors like CMR Surgical.
• The exercise price of $5.10 for the common warrants, compared to the nominal $0.0001 for pre-funded warrants, reflects a typical tiered approach to warrant pricing, often seen in growth companies to incentivize immediate capital infusion while providing longer-term upside potential.
• The 6.0% placement agent fee is within the typical range for registered direct offerings and private placements for companies of this size and stage, which can vary from 5% to 8% depending on market conditions and deal complexity.
• The lock-up period for officers and directors (30 days) is shorter than typical IPO lock-ups (90-180 days) but common for follow-on offerings, indicating a balance between market stability and insider liquidity.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution from the exercise of warrants, especially if the stock price rises above the exercise price. However, the capital raise provides funding for company operations and R&D, which could support long-term growth.
• Investors (Purchasers in Offering): Gain exposure to the company's equity with warrants providing leverage and potential upside, especially the pre-funded warrants with a nominal exercise price.
• Employees: Continued funding for R&D and operations may support job security and future growth opportunities.
• Management: Subject to lock-up agreements for 30 days, aligning their interests with short-term stock stability.
• Customers/Suppliers: Continued R&D funding could lead to new or improved products, potentially benefiting customers. Stable operations benefit suppliers.

Next Steps

• Closing of the offerings on or about October 9, 2025.
• Company to hold a stockholder meeting within 120 days of closing to seek approval for the exercise of common warrants.
• Company to file a resale registration statement on Form S-3 for the common warrant shares within 45 calendar days of the Purchase Agreement date.
• Company to use commercially reasonable efforts to have the resale registration statement declared effective within 90 calendar days of the Purchase Agreement date.
• Officers and directors will be subject to a 30-day lock-up period from the closing date.
• Company will not issue certain equity securities or enter into variable rate transactions for specified periods post-closing.

Key Dates

Recommendation

The capital raise provides essential funding for Vicarious Surgical's operations and R&D, which is crucial for a company in the development stage of robotic surgery technology. This infusion of capital helps de-risk immediate liquidity concerns and supports strategic initiatives. However, the significant potential dilution from the warrants, coupled with the requirement for stockholder approval for the common warrants, introduces uncertainty regarding the full impact on existing shareholders. While the funding is positive, the dilutive nature and the need for future approvals suggest a 'hold' recommendation, advising investors to monitor the company's progress in obtaining stockholder approval and the subsequent market reaction to warrant exercises, as well as the effective deployment of the raised capital into value-generating activities.

Keywords

Vicarious Surgical, RBOT, Registered Direct Offering, Private Placement, Warrants, Pre-funded Warrants, Common Stock, Capital Raise, SEC Filing, Robotic Surgery, Medical Technology, Dilution, Equity Financing